AngioDynamics Q1 FY2026: Med Tech sales up 26.1%; raises full-year guidance

ANGIODYNAMICS INC

2026-Q1 EPS reported -$0.26 revenue$75,711,000

Net sales $75.7M (+12.2% YoY pro forma); GAAP loss $0.26/sh, adj loss $0.10/sh.
Med Tech segment $35.3M (+26.1%): Auryon +20.1%, thrombectomy +41.2%, NanoKnife +26.7%.
Adjusted EBITDA $2.2M vs ($0.2M) prior year; cash $38.8M, debt-free.
Raised FY2026 guidance: net sales $308-$313M, adj EBITDA $6-$10M, adj EPS ($0.33)-($0.23).
Enrolled first patients in AMBITION BTK and RECOVER-AV trials; PRESERVE study published.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.